RxDoctor Payments Data

Tony Uong

Family · Bakersfield, CANPI 1497423438

Payments from drug & device makers

$444in general payments, 2019–2025

Across 16 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214
  • Gilead$49
  • Viiv Healthcare Company$37
  • Dynavax Technologies Corporation$29
  • Merck$21
  • Sanofi Pasteur Inc.$19
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$444 in reported general payments places this provider in the 55th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$286
Medicare patients
11
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$48,221
OzempicSemaglutide46$44,504
FarxigaDapagliflozin Propanediol17$15,099
TradjentaLinagliptin13$12,379
JanuviaSitagliptin Phosphate13$12,050
TrulicityDulaglutide12$11,610
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,899
Atorvastatin Calcium143$1,068
Albuterol Sulfate HfaAlbuterol Sulfate29$870
Lisinopril85$551
Levothyroxine Sodium19$432
Metformin Hcl56$336
Rosuvastatin Calcium16$278
Gabapentin29$254
Omeprazole40$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$214$44,50446 claims
AstraZenecaFarxiga$15$15,09917 claims
MerckJanuvia$21$12,05013 claims
Lilly USA, LLCTrulicity$14$11,61012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →